ey0021.10-2 | Clinical Trials – New Treatments | ESPEYB21
EL Ramos
, CM Dayan
, L Chatenoud
, Z Sumnik
, KM Simmons
, A Szypowska
, al. et
Brief Summary: This double-blind, multicenter trial randomized 328 children and adolescents (8-17 years-old) diagnosed with type 1 diabetes (T1D) within the past 6 weeks to receive either teplizumab or placebo for two 12-day courses. Teplizumab increased stimulated C-peptide levels after 1.5 years, indicating better preservation of β-cell function.Teplizumab is a monoclonal antibody that binds to CD3 on the surface of T-cells, thereby reducing the i...